10x Genomics, Inc. TXG
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 29.29% | -151.92% | 60.80% | 66.85% | 23.16% |
| Total Depreciation and Amortization | -7.70% | 23.66% | 24.12% | 14.54% | -4.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.15% | 0.87% | -24.88% | -20.37% | -14.96% |
| Change in Net Operating Assets | -121.77% | 92.44% | -81.30% | 1,450.15% | 144.54% |
| Cash from Operations | -63.36% | -4.15% | -23.96% | 704.28% | 99.69% |
| Capital Expenditure | -41.34% | -0.63% | 15.64% | 34.57% | 82.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.77% | -107.20% | -- | 101.28% | 85.24% |
| Cash from Investing | 94.28% | -723.75% | 30.74% | 96.50% | -143.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,281.85% | -14.37% | -35.31% | -50.37% | 295.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,281.85% | -14.37% | -2,094.55% | -50.37% | 295.51% |
| Foreign Exchange rate Adjustments | -448.48% | -107.78% | -164.04% | 115.99% | -121.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -32.35% | -40.79% | -50.54% | 176.27% | 90.88% |